The nitric oxide-donating pravastatin derivative, NCX 6550 [(1S-[1α(βS*,δS*),2α,6α,8β- (R*),8aα]]-1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8- (2-methyl-1-oxobutoxy)-1-naphtalene-heptanoic acid 4-(nitrooxy)butyl ester), reduces splenocyte adhesion and reactive oxygen species generation in normal and atherosclerotic mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 419-426

  Dever, G ^a   Spickett, C M ^a   Kennedy, S ^a   Rush, C ^a   Tennant, G ^a   Monopoli, A ^b   Wainwright, C L ^c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b Nicox Research Institute   (Italy)

^c ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 ALPHA 1,2,6,7,8,8 ALPHA HEXAHYDRO BETA SIGMA 6 TRIHYDROXY 2 METHYL 8 (2 METHYL 1 OXOBUTOXY) 1 NAPHTALENE HEPTANOIC ACID 4(NITROOXY)BUTYL ESTER; APOLIPOPROTEIN E; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NCX 6550; NITRIC OXIDE DONOR; PHENYLEPHRINE; PHORBOL 13 ACETATE 12 MYRISTATE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; FEMALE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL ADHESION; CHEMOKINE CCL2; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FEMALE; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE; MICE, INBRED C57BL; NITRATES; NITRIC OXIDE DONORS; PRAVASTATIN; REACTIVE OXYGEN SPECIES; SPLEEN; THROMBIN;

EID: 33845960021     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.109298     Document Type: Article

References (38)

1. Araujo FB, Barbosa DS, Hsin CY, Maranhao RC, and Abdalla DS (1995) Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis 117:61-71.
2. Ballantyne CM and Nambi V (2005) Markers of inflammation and their clinical significance. Atherosclerosis Suppl 6:21-29.
3. Bandoh T, Sato EF, Mitani H, Nakashima A, Hoshi K, and Inoue M (2003) Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. Biol Pharm Bull 26:818-822.
4. Berendji-Grun D, Kolb-Bachofen V, and Kroncke KD (2001) Nitric oxide inhibits endothelial IL-1[beta]-induced ICAM-1 gene expression at the transcriptional level decreasing Sp1 and AP-1 activity. Mol Med 7:748-754.
5. Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemostas 3:1800-1814.
6. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W, Prabhala A, Afzal A, and Garg R (2001) The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 86:355-362.
7. Davenpeck KL, Gauthier TW, and Lefer AM (1994) Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology 107:1050-1058.
8. Demiryurek AT, Kennedy S, Wainwright CL, Wadsworth RM, and Kane KA (1997) Influence of nitric oxide on luminol-enhanced chemiluminescence measured from porcine-stimulated leukocytes. J Cardiovasc Pharmacol 30:332-337.
9. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, and Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: air Force/Texas coronary atherosclerosis prevention study. J Am Med Assoc 279:1615-1622.
10. Eid HM, Lyberg T, Larsen J, Arnesen H, and Seljeflot I (2002) Reactive oxygen species generation by leukocytes in populations at risk for atherosclerotic disease. Scand J Clin Lab Investig 62:431-439.
11. Fischetti F, Carretta R, Borotto G, Durigutto P, Bulla R, Meroni PL, and Tedesco F (2004) Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 135:186-193.
12. Griendling KK, Sorescu D, and Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494-501.
13. Guzik TJ, Korbut R, and Adamek-Guzik T (2003) Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54:469-487.
14. Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, Kaplanski S, and Farnarier C (1998) Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 92:1259-1267.
15. Kennedy S, Wadsworth RM, McPhaden AR, and Wainwright CL (2000) A rapid, quantitative method for measuring leukocyte adhesion to normal and balloon-injured arteries in vitro. J Immunol Methods 244:153-162.
16. Lambeth JD (2004) NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4:181-189.
17. W, Asagami T, Matsushita H, Lee KH, and Tsao PS (2005) Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. J Pharmacol Exp Ther 313:557-562.
18. Lim SY, Tennant GM, Kennedy S, Wainwright CL, and Kane KA (2006) Activation of mouse protease-activated receptor-2 induces lymphocyte adhesion and reactive oxygen species generation. Br J Pharmacol, in press.
19. Los M, Schenk H, Hexel K, Baeuerle PA, Droge W, and Schulze-Osthoff K (1995) IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO (Eur Mol Biol Organ) J 14:3731-3740.
20. McGettrick HM, Lord JM, Wang KQ, Rainger GE, Buckley CD, and Nash GB (2006) Chemokine- and adhesion-dependent survival of neutrophils after transmigration through cytokine-stimulated endothelium. J Leukoc Biol 79:779-788.
21. Muscara MN, Lovren F, McKnight W, Dicay M, Del Soldato P, Triggle CR, and Wallace JL (2001) Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br J Pharmacol 133:1314-1322.
22. Nakashima Y, Raines EW, Plump AS, Breslow JL, and Ross R (1998) Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 18:842-851.
23. Nie Q, Fan J, Haraoka S, Shimokama T, and Watanabe T (1997) Inhibition of mononuclear cell recruitment in aortic intima by treatment with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies in hypercholesterolemic rats: implications of the ICAM-1 and LFA-1 pathway in atherogenesis. Lab Investig 77:469-482.
24. Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M, Monopoli A, Del Soldato P, and Ignarro LJ (2004) Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 101:8497-8502.
25. Orie NN, Zidek W, and Tepel M (2000) Increased intracellular generation of reactive oxygen species in mononuclear leukocytes from patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes 108:175-180.
26. Presotto C, Miglietta R, Olivieri A, and Monopoli A (2005) The nitropravastatin derivative, NCX 6550, improves endothelial dysfunction in spontaneously hypertensive rats. Circulation 112 (Suppl II):17.
27. Ramos CL, Huo Y, Jung U, Ghosh S, Manka DR, Sarembock IJ, and Ley K (1999) Direct demonstration of P-selectin- and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice. Circ Res 84:1237-1244.
28. Rossiello MR, Momi S, Caracchini R, Giannini S, Guglielmini G, Monopoli A, Ongini E, Semeraro N, Colucci M, and Gresele P (2005) A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemostas 3:2554-2562.
29. Schonbeck U and Libby P (2004) Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109: II18-II26.
30. Sellak H, Franzini E, Hakim J, and Pasquier C (1994) Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood 83:2669-2677.
31. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, and Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland coronary prevention study group. N Engl J Med 333:1301-1307.
32. Scandinavian Simvastatin Survival Study (4S) (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383-1389.
33. Stalker TJ, Lefer AM, and Scalia R (2001) A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 133:406-412.
34. Stokes KY, Cooper D, Tailor A, and Granger DN (2002) Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med 33:1026-1036.
35. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, and Nickenig G (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37:1450-1457.
36. Williams MS and Kwon J (2004) T cell receptor stimulation, reactive oxygen species, and cell signaling. Free Radic Biol Med 37:1144-1151.
37. Wolfrum S, Jensen KS, and Liao JK (2003) Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23:729-736.
38. Zeiher AM, Fisslthaler B, Schray-Utz B, and Busse R (1995) Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 76:980-986.